EGFR and non-small cell lung carcinoma: First-generation TKIs against EGFR mutated NSCLC entered development in the 1990s and entered clinical practice in 2015 when the Food and Drug Administration (FDA) approved Gefitinib on the basis of the results of several trials which showed improved outcomes in comparison to traditional chemotherapy [29,30].